Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinson’s Disease: Preclinical and Clinical Studies

Patients with Parkinson’s disease (PD) exhibit distinct gut microbiota, which may promote gut-derived inflammation. Rifaximin is a nonabsorbable antibiotic that can modify gut microbiota. The present study investigated the effect of rifaximin on gut microbiota and inflammation status in PD. The stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Chien-Tai, Chan, Lung, Chen, Kai-Yun, Lee, Hsun-Hua, Huang, Li-Kai, Yang, Yu-Chen S. H., Liu, Yun-Ru, Hu, Chaur-Jong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656351/
https://www.ncbi.nlm.nih.gov/pubmed/36359864
http://dx.doi.org/10.3390/cells11213468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656351/
https://www.ncbi.nlm.nih.gov/pubmed/36359864
http://dx.doi.org/10.3390/cells11213468

Ejemplares similares